Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Shares Pass Below 50 Day Moving Average of $0.26

Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE – Get Rating)’s share price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.26 and traded as low as $0.25. Ampio Pharmaceuticals shares last traded at $0.27, with a volume of 123,033 shares trading hands.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Ampio Pharmaceuticals in a research report on Friday, April 21st. They issued a “sell” rating for the company.

Ampio Pharmaceuticals Price Performance

The company’s 50-day moving average is $0.26 and its two-hundred day moving average is $0.23. The firm has a market cap of $4.03 million, a P/E ratio of -0.14 and a beta of 1.48.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. HRT Financial LP increased its stake in shares of Ampio Pharmaceuticals by 1,399.2% in the first quarter. HRT Financial LP now owns 217,052 shares of the specialty pharmaceutical company’s stock valued at $50,000 after buying an additional 202,574 shares during the period. Bank of Montreal Can acquired a new position in shares of Ampio Pharmaceuticals in the first quarter valued at approximately $168,000. Price T Rowe Associates Inc. MD increased its stake in shares of Ampio Pharmaceuticals by 73.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 394,100 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 166,979 shares during the period. Virtu Financial LLC acquired a new position in shares of Ampio Pharmaceuticals in the second quarter valued at approximately $72,000. Finally, Two Sigma Advisers LP increased its stake in shares of Ampio Pharmaceuticals by 304.3% in the third quarter. Two Sigma Advisers LP now owns 432,216 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 325,300 shares during the period. Institutional investors and hedge funds own 19.82% of the company’s stock.

Ampio Pharmaceuticals Company Profile

(Get Rating)

Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.